CoChat
Sign Up
Cited by 105Hepatitis B Virus StudiesIntramuscular injections and effectsVaccine Coverage and Hesitancy

Seroprotection after recombinant hepatitis B vaccination among newborn infants: A review

Schillie, Sarah F., Murphy, Trudy V.·2013·Vaccine
DOI 10.1016/j.vaccine.2012.12.012
Open this paper in CoChat — free account

Abstract

Introduction Hepatitis B vaccination starting at birth provides a safety net for infants exposed to hepatitis B virus (HBV) during delivery or in early life. Hepatitis B vaccine is recommended in the United States for infants prior to birthing facility discharge, and within the first 12h of life for infants born to hepatitis B surface antigen (HBsAg)-positive mothers. We performed a literature review and summarized the response to recombinant hepatitis B vaccine among infants.Methods Studies published between 1987 and 2011 assessing seroprotection from recombinant hepatitis B vaccine starting within the first 30 days of life were eligible. Seroprotection was defined using an antibody to hepatitis B surface antigen (anti-HBs) threshold of 10mIU/mL at series completion. Infant seroprotection was compared in trial arms varying by maternal hepatitis B antigen status (e antigen [HBeAg], HBsAg), hepatitis B immune globulin (HBIG) administration, birth weight, vaccine dosage, schedule, and age at first dose.Results Forty-three studies were included. The median seroprotection proportion overall was 98% (range 52%, 100%). The final median seroprotection proportions did not vary appreciably by maternal HBsAg status, HBIG administration, or schedule. Higher compared to lower dosage resulted in earlier increases in anti-HBs but not in final seroprotection proportions. Infants with birth weights <2000g compared to ≥2000g had lower median seroprotection proportions (93% and 98%, respectively). Median seroprotection proportions were also lower when infants with birth weights <2000g were vaccinated at 0-3 days of age compared to 1 month of age or older (68% versus 95%, respectively).Conclusion High levels of protection from recombinant hepatitis B vaccine are achieved in term infants vaccinated at birth, effectively preventing transmission of HBV and resultant morbidity and mortality. Implications, if any, for long-term protection are unknown for differences in responses among infants vaccinated at birth compared to ages older than 1 month.

Integrity signals

Registry

Crossref · 10.1016/j.vaccine.2012.12.012

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Preventive measures such as screening transfused blood for viral hepatitis, employing appropriate medical hygiene in health facilities, introducing hepatitis B vaccination programs, imposing alcohol trade restrictions and raising taxes on alcohol, and implementing health promotion and education programs to reduce alcohol consumption and harmful alcohol use are relatively inexpensive and cost-ef

    “By contrast, preventive measures such as screening transfused blood for viral hepatitis, employing appropriate medical hygiene in health facilities, introducing hepatitis B vaccination programs, imposing alcohol trade restrictions and raising taxes on alcohol, implementing health promotion and education programs to reduce alcohol consumption and harmful alcohol use are relatively inexpensive and”

    From Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis (2014) · cites this paper as [94]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Schillie, S. F., & Murphy, T. V.
Affiliations
Centers for Disease Control and Prevention (US)
Corresponding author
Schillie, Sarah F.
ORCID
Schillie, Sarah F.
Venue
Vaccine
Publisher
Elsevier BV
Published
2013-05
Volume
31
Issue
21
Pages
2506-2516
ISSN
0264-410X (ISSN-L)
DOI
10.1016/j.vaccine.2012.12.012
OpenAlex
W1975436361
Cited by
105
References
79
Citations by year
2026: 5 · 2025: 5 · 2024: 10 · 2023: 3 · 2022: 3 · 2021: 13 · 2020: 11 · 2019: 10 · 2018: 12 · 2017: 6 · 2016: 4 · 2015: 11 · 2014: 9 · 2013: 3
FWCI
0.92
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Vaccine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
  • Health Sciences › Medicine › Emergency Medicine › Intramuscular injections and effects
  • Social Sciences › Health › Vaccine Coverage and Hesitancy
Keywords
hepatitis B vaccine, neonates, seroprotection, anti-HBs antibodies, hepatitis B immunoglobulin, birth weight, vaccine dose, vaccination schedule
MeSH terms
Female, Hepatitis B, Hepatitis B Antibodies, Hepatitis B Surface Antigens, Humans, Infant, Infant, Newborn, Male, United States, Randomized Controlled Trials as Topic, Hepatitis B Vaccines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review